Open Access
Article
Biomarkers of corticosteroid-induced hypertrophic cardiomyopathy in preterm babies
Pier Paolo Bassareo1,Raul Abella1,Vassilios Fanos1,Giuseppe Mercuro1
1
Department of Cardiovascular and Neurological Sciences, University of Cagliari, Policlinico Universitario, Monserrato, Cagliari, Italy. piercard@inwind.it
DOI: 10.2741/E205 Volume 2 Issue 4, pp.1460-1471
Published: 01 June 2010
(This article belongs to the Special Issue Clinical and biochemical markers and fetal-neonatal development)
Abstract

The study of biomarkers and their signaling pathways has led to the development of new therapeutic strategies in a number of disorders. The purpose of the present systematic review is to provide an overview of different biomarkers in preterm newborns with corticosteroid-induced hypertrophic cardiomyopathy (CCHC). Several pathophysiological biomarkers are presented and discussed with the aim of investigating their diagnostic and prognostic value, particularly in relation to the potential progression of the disease and/or mortality in adulthood. This investigative approach may not only provide pathophysiological information on this serious drug-induced adverse effect, but also suggest novel therapeutic approaches to be applied in controlling its harmful consequences.

Share and Cite
Pier Paolo Bassareo, Raul Abella, Vassilios Fanos, Giuseppe Mercuro. Biomarkers of corticosteroid-induced hypertrophic cardiomyopathy in preterm babies. Frontiers in Bioscience-Elite. 2010. 2(4); 1460-1471.